Semaglutide for CKD – Does the FLOW trial impact the standard of care?

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are one of the established treatments used to slow the progression of CKD and improve outcomes.  Could perhaps the glucagon-like peptide 1 (GLP-1) receptor agonists provide similar, additive, or different benefits in patients with CKD? 

Guest Author: John Swegle, PharmD, BCPS, BCACP 

Music by Good Talk